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Basic ﬁbroblast growth factor (FGF-2)
Synthetic analogs
Glioblastoma multiforme (GBM)
Cell cultureGlioblastoma multiforme (GBM) is the most malignant form of central nervous system tumor, and cur-
rent therapies are largely ineffective at treating the cancer. Developing a more complete understanding
of the mechanisms controlling the tumor is important in order to explore new possible treatment
options. It is speculated that the presence of glioblastoma stem or stem-like cells (GSCs), a rare type of
pluripotent cancer cell that possesses the ability to self-renew and generate tumors, could be an impor-
tant factor contributing to the resistance to treatment and deadliness of the cancer. A comprehensive
knowledge of the mechanisms controlling the expression and properties of GSCs is currently lacking,
and one promising area for further exploration is in the inﬂuence of basic ﬁbroblast growth factor
(FGF-2) on GSCs. Recent studies reveal that FGF-2 plays a signiﬁcant part in regulating GBM, and the
growth factor is commonly included as a supplement in media used to culture GSCs in vitro. However,
the particular role that FGF-2 plays in GSCs has not been as extensively explored. Therefore, understand-
ing how FGF-2 is involved in GSCs and in GBMs could be an important step towards a more complete
comprehension of the managing the disease. In this review, we look at the structure, signaling pathways,
and speciﬁc role of FGF-2 in GBM and GSCs. In addition, we explore the use of FGF-2 in cell culture and
using its synthetic analogs as a potential alternative to the growth factor in culture medium.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction tumor initiation and are also known as tumor-initiating cells. TheyGlioblastoma multiforme (GBM) is the most common and most
malignant type of central nervous system (CNS) tumor with a med-
ian survival rate of less than two years [1]. Current treatments
(usually surgical resection followed by radiation or chemotherapy)
generally fail to control progression of the tumor, and recurrence is
practically inevitable [2]. It is speculated that this is partially due to
the presence of a heterogeneous cell population within the tumor,
with glioblastoma stem cells (GSCs) at the top of the hierarchy.
In recent years, there has been a growing appreciation of the
connection between oncology and stem cell biology [3]. The theory
of cancer stem cells (CSCs) stands at the nexus of these two ﬁelds
in its postulation of the existence of a specialized subset of tumor
cells that are stem cell-like [4]. Following the hierarchical model of
stem cells, CSCs are uniquely endowed with the ability to recapit-
ulate the original tumors in xenografts. They are thought to causeare largely resistant to the most advanced and rigorous modern
chemo- and radiation therapies and are thus hypothesized to be
the culprit behind the frequent tumor relapse in patients. The ﬁrst
experimental evidence for their existence and their characteristics
was demonstrated in acute myeloid leukemia in the seminal work
by Bonnet and Dick [5]. Similar evidence has emerged for solid
tumors, including breast [6], pancreatic [7,8], colon [9,10], and
brain tumors [11,12].
The existence of GSCs was ﬁrst demonstrated by Singh et al.
[11,12]. Galli et al. similarly demonstrated that glioblastoma cell
lines possess molecular, cytologic, and histologic characteristics
similar to neural stem cells (NSCs) [13]. Like other CSCs, GSCs are
especially endowed with the ability to resist radiation therapy
[14–17]. For example, GSCs were shown to possess higher capacity
to activate DNA damage checkpoint proteins and thereby are more
radiation resistant than non-GSCs [14]. To overcome GSC radiation
resistance, DNA damage checkpoint activation [14], Notch signal-
ing [18], HSP90 activity [19], and Wnt/b-catenin signaling [20]
have been suggested as possible targets. Many of these pathways
are important in non-tumorigenic normal stem cells [4] and thus
further highlight the connection between stem cell biology and
oncology.
Generally, the role of receptor tyrosine kinases (RTKs) in GBM
has been well-documented. The most extensively studied RTK in
2 E.M. Haley, Y. Kim / Cancer Letters 346 (2014) 1–5GBM is the epidermal growth factor receptor (EGFR). Either an
ampliﬁcation or variant spliced form of EGFR (i.e. EGFRvIII) is
found in more than half of the patients and has been linked with
aggressive subtypes of GBM [21,22]. The roles of additional RTKs,
on the other hand, have not been as extensively studied. A growing
recognition of their importance has developed, since, for example,
RTKs such as the platelet derived growth factor a (PDGFRA), hepa-
tocyte growth factor receptor (HGFR/MET), and ﬁbroblast growth
factor receptor (FGFR) were also found to be frequently altered
or ampliﬁed [23]. Increasing evidence demonstrates the roles and
importance of FGFs in GBM; however, the role of FGFR in glioblas-
toma stem cell (GSC) biology is less well understood. A better
insight into the FGFR/ﬁbroblast growth factor (FGF) axis provides
an opportunity to improve our overall comprehension of GSCs.
This review will therefore primarily focus on the role of basic
FGF (bFGF/FGF-2) in GBM and GSCs. Emerging evidence demon-
strates the critical role of FGF signaling in GBM and GBM stem
cell-like cell lines [24,25]. It is also important to mention that
FGF-2, along with epidermal growth factor (EGF), is an essential
component of in vitro culture media for NSCs and GSCs [12,26].
We will explore the current understanding of FGF-2, its signaling
pathways, its downstream effects, and its use in GSC culture.2. Structure and isoforms of basic ﬁbroblast growth factor
The FGF superfamily is made up of 22 different ﬁbroblast
growth factor genes [27]. Basic FGF (FGF-2) and acidic FGF (FGF-
1) are unique in that they do not follow the conventional signal se-
quence for secretion [28]. Furthermore, FGF-2 is found in several
isoforms. Five known isoforms of FGF-2 exist via alternative initia-
tion of translation. The 18 kDa low molecular weight (lmw) form
follows the classic Kozak initiation AUG codon. Four upstream
CUG start codons generate high molecular weight (hmw) forms
of 22, 22.5, 24, and 34 kDa FGF-2. While the lmw form can be se-
creted, the high molecular weight isoforms cannot. They remain
in either the cytosol or the nucleus. The secreted FGF-2 can be
internalized by target cells and are translocated into their cyto-
plasm and nucleus [29]. Further details on the role of different iso-
forms can be found in an excellent review by Sorensen et al. [28].
More speciﬁcally to our discussion here, it was found that the nu-
clear accumulation of hmw FGF-2 is associated with glioma cell
proliferation [30]. The lmw FGF-2 was also reported to have a sim-
ilar effect once internalized, by being regulated by FGF-2 interact-
ing translokin and gaining a C-terminal nuclear localization
sequence for speciﬁc targeting to the nucleus [31]. It is still unclear
how each of the FGF-2 isoforms correlates with stem cell pheno-
type maintenance and remains to be elucidated. If a speciﬁc
isoform can be linked to GSC enrichment, it has interesting poten-
tial to generate GSC-speciﬁc analogs (see Section 5) or a more
optimal media development for their growth in vitro.3. Basic ﬁbroblast growth factor signaling pathways in
glioblastoma and glioblastoma stem cells
FGF-2 can undergo several alternate signaling pathways
depending on the isoform, localization, and cell conditions.
Endogenous lmw FGF-2 can be released from the cell and can sig-
nal either in autocrine or in paracrine manner. It lacks a deﬁnitive
secretion signal sequence and is released by an ER/Golgi-inde-
pendent mechanism that relies on its association with other mol-
ecules [32]. Lmw FGF-2 signals through the ﬁbroblast growth
factor receptors (FGFRs) and binds primarily to FGFR-1 and
FGFR-2 [32]. Lmw FGF-2 ﬁrst binds to heparin sulfate proteogly-
cans (HSPGs), and this complex then binds to the FGFR, inducing
a signal transduction pathway [33]. The formation of the primaryFGF-2/HSPG complex is necessary to stabilize FGFR dimerization
[34]. Several different signaling pathways can be activated
depending on the downstream formation of multi-docking sig-
naling complexes via tyrosine phosphorylation [32]. The docking
protein FRS2 is responsible for recruiting a majority of proteins
involved in FGF-2 signaling pathways. A total of six Grb2 mole-
cules are recruited either directly by FRS2 or indirectly by a
FRS2/Shp2 complex. Grb2 molecules then recruit either SOS,
which leads to activation of the Ras-MAKP pathway, or Gab1,
which leads to activation of the PI3K-Akt pathway [33], which
is associated with proliferation [35], angiogenesis [36], and sur-
vival [37].
FGF-2 is known to modulate the apoptosis pathways [38] and
thereby promotes survival via resistance to radiation induced cell
death [39]. For carcinoma stem cells deﬁned as Hoechst dye efﬂux-
ing side population (SP) cells, the FGF-2 pathway was found to af-
fect DNA repair [40]. In addition, the SP was found to have a highly
constitutive active expression of FGF-2, again signifying the impor-
tance of FGF-2 in CSCs.
In a recent study looking at GBM, it was found that secretion
of FGF-2 by GBM cells enhances the blood brain barrier function
of endothelial cells, which also contributes to drug resistance in
GBM [41]. Anti-FGF treatment has been found to have anti-prolif-
erative and anti-angiogenic effects in glioma cell lines [42,43].
GBM is one of the most highly vascularized cancers [44], and
FGF-2 acts as an important contributor in the process of angio-
genesis [45]. The growth factor promotes angiogenesis directly
by activating proliferation and migration of endothelial cells
and indirectly by upregulating urokinase-type plasminogen acti-
vator, which also leads to cell migration [46]. A recent study re-
ports that survivin, a protein that promotes angiogenesis could
trigger the release of FGF-2, along with VEGF, in gliomas and
thereby stimulate an increase in growth and proliferation in the
tumors [47]. For further discussion of FGFs and FGFRs, as well
as a summary of currently existing anti-FGF therapies for cancer,
we refer the readers to the comprehensive review by Turner and
Grose [48].
Speciﬁcally for GSCs, FGF-2 helps to maintain their stem cell
state. Its removal from glioma stem cell lines has been shown to re-
sult in differentiation, which was not seen when the cells were in
the presence of the growth factor [49]. It was recently found that
FGF-2 is effective at inducing Nestin, a protein marker for neural
stem cells, in C6 glioma cells. This again suggests that FGF-2 con-
tributes to the stemness of glioma cells [50]. Autocrine production
of FGF-2 in combination with EGF may also be responsible for
retaining the self-renewal potential of GSCs [51].
On the other hand, FGF-2 has been shown to maintain the
presence of SP cells in the C6 glioma cell line but was unable to
stimulate proliferation without the additional presence of PDGF
[52]. Furthermore, GSCs that speciﬁcally bear molecular similari-
ties to highly proliferative cell lines were able to rapidly grow in
the absence of FGF-2 [53]. These ﬁndings suggest that the role of
FGF-2 is complex or at least that the murine GSCs may have mech-
anisms redundant to FGF-2 signaling to maintain their prolifera-
tion. Unfortunately, current lack of studies make it premature to
comment whether similar ambiguity exists with FGF-2 and human
GSCs. The complete role FGF-2 plays in GSCs is thus still largely
uncharacterized, and further studies need to be done to uncover
its exact effects.
4. Usage of basic ﬁbroblast growth factor in cancer stem cell
culture
The use of FGF-2 for in vitro culture of GSCs was ﬁrst established
by noting the similarity in culture conditions with neural stem
cells [11,13,54]. Lee et al. [26] provided phenotypic and genetic
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maintain GSC characteristics in vitro. More recently Lathia et al.
[55] also demonstrated that FGF-2 is critical in maintaining sym-
metrical propagation of CD133 + GSCs in vitro, and that its removal
leads to at least twice as many non-stem heterogeneous progeny
than at basal levels. Furthermore, of the two exogeneous growth
factors used in culture, FGF-2 had a more signiﬁcant impact than
EGF in promoting growth in vitro [56]. It is interesting to also note
that FGF-2 was found to be important in mediating DNA repair in
other cancer cells and CSCs, such as the HeLa cells [57], epidermal
stem cells [58,59], and epidermoid carcinoma stem cells [40]. The
SP of A549 and H460 non-small cell lung cancer cells also were
found to have elevated levels of autocrine FGF-2 [60].
However, a few studies questioned the necessity of adding
FGF-2 as a supplement to the GSC in vitro media. Li et al. [51]
found that primary GBM cells cultured in medium without
growth factors still possessed a population of GSCs. Furthermore,
they showed that GBM cells expressed FGF-2, suggesting that
secretion and autocrine expression of FGF-2 by GSCs may be en-
ough to support growth without the added media supplements.
Kelly et al. [61] also found that primary GBM cells can form neur-
ospheres in culture without adding FGF-2 and EGF to the media;
however, addition of the growth factors coincided with an in-
crease in sphere proliferation and survival. A more recent study
demonstrated that GBM sphere formation increased in the ab-
sence of the growth factors and decreased in their presence
[62]. It is worth noting, however, that phenotypic alterations in
the GBM cells were observed when the exogenous growth factors
were added to the media [61]. Maintaining GSCs in vitro that are
similar to the original tumor cells is critically important, so avoid-
ing any unnecessary alterations should be a top priority when
developing culture methods. Therefore, further investigation is
needed to determine if the beneﬁts of using FGF-2 in GSC culture
outweigh its disadvantages.Table 1
FGF-2 and its patented synthetic analogs.
Peptide Inventor Amino acid sequence
bFGF – MAAGSITTLPALPEDGGSGAFPPGHFKDPK
CANRYLAMKEDGRLLASKCVTDECFFFERL
bFGF-C78/96S Fiddes et al. MAAGSITTLPALPEDGGSGAFPPGHFKDPK
SANRYLAMKEDGRLLASKSVTDECFFFERLG
C19jun Ballinger et al. AESGDDYCVLVFTDSAWTKICDWSHFRN
ANMLREQVAQLKQKVMNHGGCGGSGGH
F2A3 Pena et al. K – Hex-Hex-Hex-RKRKLERIAR
|
NRFHSWDCIKTWASDTFVLVCYDDGSEA
F2A4 Pena et al. K – Hex-Hex-Hex-RKRKLERIAR
|
YRSRKYSSWYVALKR
FGF-P Okunieff et al. CYRSRKYSSWYVALKRC
Hex = aminohexanoic acid. Underlined = identical sequence to natural FGF-2. Bold = ide
with Ser.
Table 2
Approximate cost of GSC media and its components.






Heparin Fisher Scientiﬁc $0.01/lg
Neurobasal-A medium Invitrogen $0.12/mL
Total5. Comparison of current synthetic analogs of basic ﬁbroblast
growth factor
Several different peptides that exhibit similar, but improved
biological effects as FGF-2 have been developed, and use of these
synthetic analogs rather than FGF-2 in cell culture media could
possibly lead to enhanced and more proliferative growth condi-
tions (Table 1). One of the ﬁrst effective analogs was designed by
Ballinger et al. [63]. They designed a peptide named C19jun, which
is the combination of a unique 26-residue peptide that can bind
FGFR (C19) and a protein domain that can both bind heparin and
promote dimerization. Utilizing the same C19 sequence, Pena
et al. [64] designed a peptide, F2A3, which combines C19 with an
18 alkyl carbon hydrophobic region connected to a heparin binding
domain. An additional analog, F2A4, which is identical to F2A3 ex-
cept the C19 region is replaced by amino acids 115-129 of FGF-2,
was also designed by the same group. When used as a supplement
in media, usage of both F2A3 and F2A4 corresponded with higher
rates of proliferation than FGF-2, with F2A4 being the highest
[64,65]. Another analog, FGF-P, designed by Okunieff et al. has also
been shown to improve stem cell survival and proliferation. This
17 amino acid peptide consists of an FGFR binding domain as well
as a linking element to allow for receptor dimerization [66].
FGF-2 in media plus the heparin supplement needed to stabilize
the growth factor [67] accounts for a large percentage (30% to
40%) of the cost associated with culturing GSCs in vitro (Table 2).
Therefore, developing cost-reducing methods for cell culture is an-
other area that synthetic analogs could theoretically show
improvement over recombinant FGF-2. It has been proposed that
modifying cysteine residues in FGF proteins could decrease the
occurrence of incorrect disulﬁde bridge formation, therefore elim-
inating the need for reducing agents for FGF stabilization [68,69].
This could not only remove the need for a heparin supplement













ntical sequence between C19jun and F2A3. Bold+underlined = substitution of Cys
Amount used in media Total cost References
10–20 ng/mL $100-$200/L [72,73]
10–20 ng/mL $10-$20/L [72,73]
2.5 mL/L $0.50/L [74]
5 mL/L $75/L [74]
10 mL/L $100/L [72]
5 lg/mL $50/L [74]
1 L $120/L [72]
$500-$600/L
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[69]. Fiddes et al. demonstrated this with their analog bFGF-C78/
96S (cysteine residues at amino acids 78 and 96 are replaced by
serine residues) that possesses the ability to stimulate higher rates
of proliferation than recombinant FGF-2 [69].
Many of these analogs are easier to recover in large, pure quan-
tities due to their small size and exhibit greater stability due to
alterations in their amino acid sequences as compared to recombi-
nant FGF-2, which could lead to a longer shelf life [69]. These ana-
logs are still in development phase and are not yet commercially
available, and thus their cost ﬁgures are not accessible. However,
the enhanced stability of some peptides and possible requirement
for a smaller media supplement due to increased biological activity
suggests that synthetic analogs may potentially be able to elimi-
nate some of the cost associated with FGF-2 use in culture media.
Synthetic analogs could be an interesting alternative for in vitro
culture, and the option should further be explored.6. Conclusions
With a median survival rate of less than two years, the outcome
of most cases of glioblastoma multiforme is a very bleak [1]. In or-
der to improve the prognosis for GBM patients, new therapeutic
targets should be explored when developing future treatment op-
tions. Two promising areas for exploration are FGF-2 and GSCs.
FGF-2 has come to light as a growth factor that plays a signiﬁcant
role in the progression of GBM, contributing to proliferation, angi-
ogenesis, and survival. The growth factor also contributes to drug
resistance in GBM, as does the relentless presence of GSCs. Thera-
pies targeting FGF-2 could potentially be effective at destroying
GSCs, as it has been discovered that the growth factor is important
in preserving the stemness of GSCs [49]. Before this can be done,
however, a clearer understanding of FGF-2’s exact role in GSCs is
essential. Future research should focus on deﬁning this role.
The use of FGF-2 as a supplement in GSC culture medium has
become a widely accepted practice. Most agree that the growth fac-
tor is critical in order to retain stemness in vitro; however, the
growth factor may lead to unwanted phenotypic variations in GSCs
[61]. Developing treatments based on cells that are unlike those
found in primary tumors may lead to therapies that are ineffective
in practice. A close examination of the effects of FGF-2 on phenotype
shouldbe a priority in order to conﬁrm its usefulness as amedia sup-
plement and prevent avoidable mistakes in new drug development.
Studying the effects of synthetic analogs that mimic FGF-2 is
another interesting area for potential development. The possibility
of enhanced biological activity induced by analogs as compared to
recombinant FGF-2 could improve growth conditions and/or re-
duce the amount of supplement needed in media. In addition,
many of these analogs show improved stability over recombinant
FGF-2, which could prolong shelf life or eliminate the need for a
heparin supplement in media. The costly nature of recombinant
FGF-2 and heparin in part accounts for the limited availability of
GSCs for research use, and these factors suggest that analogs may
be able to eventually reduce the cost, making GSCs more easily
accessible. As with recombinant FGF-2, studying the phenotypic ef-
fects of any potential analogs would also be important to ensure no
signiﬁcant alterations are caused by the agonists.
Many opportunities exist in improving our understanding of the
role of FGF-2 in GSCs. Exploring each of these areas could prove to
be very important in the advancement of GBM treatments and GSC
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